HILS vs. XBIT, GALT, BMEA, ANIX, CLYM, VIRI, ATOS, ADAG, HURA, and MIST
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include XBiotech (XBIT), Galectin Therapeutics (GALT), Biomea Fusion (BMEA), Anixa Biosciences (ANIX), Climb Bio (CLYM), Virios Therapeutics (VIRI), Atossa Therapeutics (ATOS), Adagene (ADAG), TuHURA Biosciences (HURA), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
Hillstream BioPharma vs.
Hillstream BioPharma (NASDAQ:HILS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, XBiotech had 1 more articles in the media than Hillstream BioPharma. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Hillstream BioPharma. XBiotech's average media sentiment score of 1.89 beat Hillstream BioPharma's score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.
Hillstream BioPharma has higher earnings, but lower revenue than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks.
13.4% of Hillstream BioPharma shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by company insiders. Comparatively, 33.1% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
XBiotech's return on equity of -15.99% beat Hillstream BioPharma's return on equity.
Hillstream BioPharma has a beta of 3.08, indicating that its share price is 208% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
XBiotech received 316 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote.
Summary
XBiotech beats Hillstream BioPharma on 9 of the 13 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:HILS) was last updated on 3/12/2025 by MarketBeat.com Staff
